CHI3L1 predicted in malignant entities is associated with glioblastoma immune microenvironment

• DOI: 10.1016/j.clim.2022.109158
• Publication Date: 2022-10-14T11:36:34Z
• Authors: Fei Li; Bing Qi; Le Yang; Bao Wang; Li Gao; Minggao Zhao; Lanxin Luo
• Keywords: Gene Expression Regulation, Neoplastic; 03 medical and health sciences; Gene Ontology; 0302 clinical medicine; Brain Neoplasms; Tumor Microenvironment; Humans; Glioma; Chitinase-3-Like Protein 1; Glioblastoma; 3. Good health

Effective immunotherapies for patients with glioblastoma (GBM) are urgently needed. Chitinase-3 like-protein-1 (CHI3L1) play important roles in the development of gliomas. However, its role in glioma-related immune responses remains unclear. We aimed to comprehensively investigate its biological features and clinical value in glioma, especially in GBM. Transcriptome, proteome and single-cell RNA-sequencing databases were enrolled in the study. Immunostaining and immunoblotting were performed for validation. CHI3L1 was highly correlated with clinical and molecular features, suggesting that high CHI3L1 expression is more likely to be predicted as malignant entities. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed CHI3L1 closely associated with immune responses and inflammatory activities in GBM. In addition, CHI3L1 also correlated with immune cell infiltration and immune checkpoints. Our study suggests that inhibition of CHI3L1 may help to reduce immunosuppression and overcome immunotherapy resistance, which would be an therapeutic area for the treatment of GBM.